New and future antibiotics in the treatment of acute respiratory tract infections.
作者信息
Wise R
出版信息
Thorax. 1995 Mar;50(3):223-4. doi: 10.1136/thx.50.3.223.
Abstract
摘要
相似文献
1
New and future antibiotics in the treatment of acute respiratory tract infections.用于治疗急性呼吸道感染的新型及未来抗生素
Thorax. 1995 Mar;50(3):223-4. doi: 10.1136/thx.50.3.223.
2
Efficacy of co-amoxiclav compared with other beta-lactams, quinolones, tetracyclines and erythromycin against an experimental Chlamydia trachomatis respiratory infection.与其他β-内酰胺类、喹诺酮类、四环素类和红霉素相比，阿莫西林克拉维酸对实验性沙眼衣原体呼吸道感染的疗效。
J Antimicrob Chemother. 1993 Nov;32(5):781-2. doi: 10.1093/jac/32.5.781.
3
[Recommendations for the indication-justified application of antibiotics. 2. Aminoglycosides, quinolones, tetracyclines].
Z Arztl Fortbild (Jena). 1991 Aug 26;85(16):743-6.
4
The use of oral antibiotics in lower-extremity infections.口服抗生素在下肢感染中的应用。
Clin Podiatr Med Surg. 1996 Oct;13(4):683-99.
5
Antibiotics.
RN. 1997 Oct;60(10):49-54; quiz 55.
6
Quinolones and macrolides: roles in respiratory infections.喹诺酮类和大环内酯类：在呼吸道感染中的作用
Hosp Pract (Off Ed). 1993 Jan 15;28(1):149-153, 156-62. doi: 10.1080/21548331.1993.11442744.
7
A guide to the treatment of lower respiratory tract infections.下呼吸道感染治疗指南
Drugs. 1995 Jul;50(1):62-72. doi: 10.2165/00003495-199550010-00006.
8
Have we reached the point of no return? The hidden impact of antibacterial resistance in respiratory tract infection. Introduction.
Respir Med. 2001 Jun;95 Suppl A:S2-4; discussion S26-7. doi: 10.1016/s0954-6111(01)90021-6.
9
[Microorganisms and coronary heart disease. Do antibiotics protect against cardiac events?].[微生物与冠心病。抗生素能预防心脏事件吗？]
MMW Fortschr Med. 2002 Oct 10;144(41):41-2.
10
Quinolones in the treatment of lower respiratory tract infections in adult patients.
Drugs. 1993;45 Suppl 3:91-7. doi: 10.2165/00003495-199300453-00016.
引用本文的文献
1
Comparison of amoxycillin and clarithromycin as initial treatment of community-acquired lower respiratory tract infections.阿莫西林与克拉霉素作为社区获得性下呼吸道感染初始治疗药物的比较。
Br J Gen Pract. 1996 Jun;46(407):357-60.
2
The appropriate use of quinolones.喹诺酮类药物的合理使用。
Drugs. 1996;52 Suppl 2:34-6. doi: 10.2165/00003495-199600522-00007.
本文引用的文献
1
Randomized placebo-controlled trials of antibiotics for acute bronchitis: a critical review of the literature.抗生素治疗急性支气管炎的随机安慰剂对照试验：文献综述
J Fam Pract. 1993 May;36(5):507-12.
2
In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.新型氟喹诺酮类药物CP-99,219对革兰氏阳性菌临床分离株的体外活性
Antimicrob Agents Chemother. 1993 Feb;37(2):366-70. doi: 10.1128/AAC.37.2.366.
3
The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.新型5-甲基取代喹诺酮OPC-17116的体外活性
J Antimicrob Chemother. 1993 Apr;31(4):497-504. doi: 10.1093/jac/31.4.497.
4
In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines.新型半合成四环素类——甘氨酰环素的体外和体内抗菌活性
Antimicrob Agents Chemother. 1993 Nov;37(11):2270-7. doi: 10.1128/AAC.37.11.2270.
5
The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po.单剂量静脉注射400毫克环丙沙星与口服750毫克环丙沙星的比较药代动力学及组织穿透性。
J Antimicrob Chemother. 1994 Jan;33(1):103-10. doi: 10.1093/jac/33.1.103.
6
The in-vitro activity of a new highly active quinolone, DU-6859a.新型高效喹诺酮DU-6859a的体外活性
J Antimicrob Chemother. 1993 Nov;32(5):757-63. doi: 10.1093/jac/32.5.757.
7
In vitro activities of two glycylcyclines.两种甘氨酰环素的体外活性
Antimicrob Agents Chemother. 1994 May;38(5):1096-102. doi: 10.1128/AAC.38.5.1096.
8
The levels of clarithromycin and its 14-hydroxy metabolite in the lung.肺中克拉霉素及其14 - 羟基代谢物的水平。
Eur Respir J. 1994 Jul;7(7):1275-80. doi: 10.1183/09031936.94.07071275.
9
Bacteriology of hospital-acquired pneumonia.医院获得性肺炎的细菌学
Arch Intern Med. 1986 May;146(5):868-71.
10
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.慢性阻塞性肺疾病急性加重期的抗生素治疗
Ann Intern Med. 1987 Feb;106(2):196-204. doi: 10.7326/0003-4819-106-2-196.
Zotero 插件